Patents-Review.com
🔗 Permalink
Assignee profile:

SIGNPATH PHARMA INC.

City:

Sandy, Utah

Country:

United States

Published Applications:

18

Last publication date:

2024-02-15

Patent Grants:

18

Last grant date:

2026-02-17

Top Inventors for applications by SIGNPATH PHARMA INC.

These are the the leading inventors for applications assigned to SIGNPATH PHARMA INC.:

Recent patent applications by SIGNPATH PHARMA INC.

SIGNPATH PHARMA INC. based in Sandy, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-02-15 ✅ Patent 12,551,436 granted on 2026-02-17
US20240050372A1
Human necessities

Dosing Regimens for Treatment of Proliferative Disorders

 #2 | 2023-02-09 ✅ Patent 12,617,809 granted on 2026-05-05
US20230042703A1
Chemistry; metallurgy

Cardioprotective Lipid and Method of Use

 #3 | 2022-02-24 ✅ Patent 11,746,119 granted on 2023-09-05
US20220056057A1
Chemistry; metallurgy

Cardiopathy-reducing phosphodiester lipids

 #4 | 2021-07-01 ✅ Patent 11,643,424 granted on 2023-05-09
US20210198294A1
Chemistry; metallurgy

Cardiopathy-reducing phosphodiester lipids

 #5 | 2021-06-03 ✅ Patent 11,813,356 granted on 2023-11-14
US20210161815A1
Human necessities

Dosing regimens for treatment of proliferative disorders

 #6 | 2019-12-26 ✅ Patent 10,975,111 granted on 2021-04-13
US20190389888A1
Chemistry; metallurgy

Cardiopathy-reducing phosphodiester lipids

 #7 | 2019-10-24 ✅ Patent 12,004,868 granted on 2024-06-11
US20190320975A1
Human necessities

Liposomal mitigation of drug-induced inhibition of the cardiac Ichannel

 #8 | 2018-03-01 ✅ Patent 10,238,602 granted on 2019-03-26
US20180055770A1
Human necessities

Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies

 #9 | 2017-11-02 ✅ Patent 11,806,401 granted on 2023-11-07
US20170312366A1
Human necessities

Prevention of drug-induced atrio-ventricular block

 #10 | 2017-08-31 ✅ Patent 10,357,458 granted on 2019-07-23
US20170246110A1
Human necessities

Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current

 #11 | 2017-04-06 ✅ Patent 10,117,881 granted on 2018-11-06
US20170095489A1
Human necessities

Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies

 #12 | 2017-03-23 ✅ Patent 10,485,768 granted on 2019-11-26
US20170079934A1
Human necessities

Treatment for glioblastoma

 #13 | 2017-02-09 ✅ Patent 10,449,193 granted on 2019-10-22
US20170035887A1
Human necessities

Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies

 #14 | 2016-07-07 ✅ Patent 10,617,639 granted on 2020-04-14
US20160193149A1
Human necessities

Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current

 #15 | 2016-06-30 ✅ Patent 10,739,353 granted on 2020-08-11
US20160184330A1
Human necessities

Suppression of cytokine release and cytokine storm

 #16 | 2015-12-03 ✅ Patent 10,258,691 granted on 2019-04-16
US20150343063A1
Human necessities

Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies

 #17 | 2015-06-18 ✅ Patent 10,532,045 granted on 2020-01-14
US20150164878A1
Human necessities

Liposomal mitigation of drug-induced inhibition of the cardiac Ichannel

 #18 | 2014-10-30 ✅ Patent 10,004,687 granted on 2018-06-26
US20140322303A1
Human necessities

Liposomal curcumin for treatment of diseases

Also check out SignPath Pharma Inc.'s (Sandy, United States) applicant profile with 12 patent applications submitted.

AssigneeID:

540686 ⎘